Type I consensus interferon (CIFN) gene transfer into human melanoma cells up-regulates p53 and enhances cisplatin-induced apoptosis: Implications for new therapeutic strategies with IFN-alpha

Gene Therapy

Volumn 7, Issue 2, 2000, Pages 167-179

  Mecchia, M ^a   Matarrese, P ^a   Malorni, W ^a   D'Agostino, G ^a   Sestili, P ^a   Santini, S M ^a   Gauzzi, M C ^a   Venditti, M ^a   Mazzocchi, A ^b   Parmiani, G ^b   Belardelli, F ^a   Ferrantini, M ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Cisplatin; Gene transfer; IFN ; Melanoma; p53

Indexed keywords

ALPHA INTERFERON; CISPLATIN; PROTEIN BCL 2; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL CULTURE; CONSENSUS SEQUENCE; CONTROLLED STUDY; DRUG EFFICACY; GENE THERAPY; GENE TRANSFER; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; MALE; MELANOMA CELL; METASTASIS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 12944333194     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301059     Document Type: Article

References (50)

1. Cohen GL, Falkson CI. Current treatment options for malignant melanoma. Drugs 1998; 55: 791-799.
2. Kirkwood JM et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14: 7-17.
3. Weiss K. Safety profile of interferon-alpha therapy. Semin Oncol 1998; 25: 9-13.
4. Hussein AM. The potential application of gene transfer in the treatment of patients with cancer: a concise review. Cancer Invest 1996; 14: 343-352.
5. Pfeffer LM et al. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res 1998; 58: 2489-2499.
6. Belardelli F. Role of interferons and other cytokines in the regulation of the immune response. APMIS 1995; 103: 161-179.
7. 1-interferon gene transfer into metastatic Friend leukemia cells abrogated tumorigenicity in immunocompetent mice: antitumor therapy by means of interferon-producing cells. Cancer Res 1993; 53: 1107-1112.
8. Ferrantini M et al. IFN-alpha1 gene expression into a metastatic murine adenocarcinoma (TS/A) results in CD8+ T cell-mediated tumor rejection and development of antitumor immunity. Comparative studies with IFN-gamma producing TS/A cells. J Immunol 1994; 153: 4604-4615.
9. 1 gene transfection completely abolishes the tumorigenicity of murine B16 melanoma cells in allogeneic DBA/2 mice and decreases their tumorigenicity in syngeneic C57BL/6 mice. Int J Cancer 1995; 60: 1-9.
10. 1 transfected Friend Leukemia cells. Am J Pathol 1995; 147: 445-460.
11. Sarkar S et al. Injection of irradiated melanoma genetically modified to secrete IFN-α causes regression of an established tumor. Int J Oncol 1995; 7: 17-24.
12. Tüting T et al. Interferon-α gene therapy for cancer: retroviral transduction of fibroblasts and particle-mediated transfection of tumor cells are both effective strategies for gene delivery in murine tumor models. Gene Therapy 1997; 4: 1053-1060.
13. 1 gene transduced ESb tumor cells are rejected by host-mediated mechanisms despite the resistance of the parental tumor to IFN-α/β therapy. Cancer Gene Ther 1999; 6: 246-253.
14. Belldegrun A et al. Human renal carcinoma line transfected with interleukin-2 and/or interferon alpha gene(s): implications for live cancer vaccines. J Natl Cancer Inst 1993; 85: 207-216.
15. Cao X et al. Treatment of human hepatocellular carcinoma by fibroblasts-mediated human interferon alpha gene therapy in combination with adoptive chemoimmunotherapy. J Cancer Res Clin Oncol 1995; 121: 457-462.
16. Wang J et al. Treatment of leukemia with fibroblasts-mediated interferon-alpha gene therapy alone or in combination with doxorubicin. Leukemia Res 1996; 20: 379-384.
17. Zhang JF et al. Gene therapy with an adeno-associated virus carrying an interferon gene results in tumor growth suppression and regression. Cancer Gene Ther 1996; 3: 31-38.
18. Santodonato L et al. Cure of mice with established metastatic Friend leukemia cell tumors by a combined therapy with tumor cells expressing both interferon-α1 and Herpes simplex thymidine kinase followed by ganciclovir. Hum Gene Ther 1996; 7: 1-10.
19. Santodonato L et al. Local and systemic antitumor response after combined therapy of mouse metastatic tumors with tumor cells expressing IFN-α and HSVTK: perspectives for the generation of cancer vaccines. Gene Therapy 1997; 4: 1246-1255.
20. Sulé-Suso J et al. A B7-1-transfected human melanoma line stimulates proliferation and cytotoxicity of autologous and allogeneic lymphocytes. Eur J Immunol 1995; 25: 2737-2742.
21. Arienti F et al. Interleukin-2 gene-transduced human melanoma cells efficiently stimulate MHC-unrestricted and MHC-restricted autologous lymphocytes. Hum Gene Ther 1994; 5: 1139-1150.
22. Nguyen H, Lin R, Hiscott J. Activation of multiple growth regulatory genes following inducible expression of IRF-1 or IRF/RelA fusion proteins. Oncogene 1997; 15: 1425-1435.
23. Favrot M, Coll J-L, Louis N, Negoescu A. Cell death and cancer: replacement of apoptotic genes and inactivation of death suppressor genes in therapy. Gene Therapy 1998; 5: 728-739.
24. Li G et al. Chemotherapy-induced apoptosis in melanoma cells is p53 dependent. Melanoma Res 1998; 8: 17-23.
25. Davol PA, Goulette FA, Frackelton AR Jr, Darnowsky JW. Modulation of p53 expression by human recombinant interferon-α2a correlates with abrogation of cisplatin resistance in a human melanoma cell line. Cancer Res 1996; 56: 2522-2526.
26. Hansen R, Oren M. p53; from inductive signal to cellular effect. Curr Opin Genet Dev 1997; 7: 46-51.
27. Strasser A, Huang DCS, Vaux DL. The role of the bcl-2/ced-9 gene family in cancer and general implications of defects in cell death control for tumourigenesis and resistance to chemotherapy. Biochim Biophys Acta 1997; 1333: F151-F178.
28. Wadler S. The role of interferons in the treatment of solid tumors. Cancer 1992; 70: 949-958.
29. Thomas H, Balkwill FR. Effects of interferons and other cytokines on tumors in animals: a review. Pharmacol Ther 1991; 52: 307-330.
30. Tanaka N et al. Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1. Cell 1994; 77: 829-839.
31. Kumar A et al. Deficient cytokine signaling in mouse embryo fibroblasts with a targeted deletion in the PKR gene: role of IRF-1 and NF-κB. EMBO J 1997; 16: 406-416.
32. Tamura T et al. Interferon-gamma induces Ice gene expression and enhances cellular susceptibility to apoptosis in the U937 leukemia cell line. Biochem Biophys Res Commun 1996; 229: 21-26.
33. Giandomenico V et al. Retinoic acid and IFN inhibition of cell proliferation is associated with apoptosis in squamous carcinoma cell lines: role of IRF-1 and TGase II-dependent pathways. Cell Growth Differ 1997; 8: 91-100.
34. Kumar A et al. Defective TNF-α-induced apoptosis in STAT1-null cells due to low constitutive levels of caspases. Science 1997; 278: 1630-1632.
35. Lotem J, Sachs L. Cytokine suppression of protease activation in wild-type p53-dependent and p53-independent apoptosis. Proc Natl Acad Sci USA 1997; 94: 9349-9353.
36. Belardelli F, Gresser I. The neglected role of type I interferon in the T-cell response: implications for its clinical use. Immunol Today 1996; 17: 369-372.
37. Tough DF, Borrow P, Sprent J. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 1996; 272: 1947-1950.
38. 1 into syngeneic mice. Cancer Res 1998; 58: 5795-5802.
39. Romagnani S. Induction of Th1 and Th2 responses: a key role for the 'natural' immune response? Immunol Today 1992; 13: 379-381.
40. Rogge L et al. Selective expression of an interleukin-12 receptor component by human T helper 1 cells. J Exp Med 1997; 485: 825-830.
41. Luft T et al. Type I IFN enhance the terminal differentiation of dendritic cells. J Immunol 1998; 161: 1947-1953.
42. Paquette RL et al. Interferon-α and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells. J Leukoc Biol 1998; 64: 358-367.
43. Tuting T et al. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-α. J Immunol 1998; 160: 1139-1147.
44. Gnjatic S et al. Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinomas and melanomas. J Immunol 1998; 160: 328-333.
45. McCarty TM et al. Targeting p53 for adoptive T-cell immunotherapy. Cancer Res 1998; 58: 2601-2605.
46. Miller AD, Rosman GJ. Improved retroviral vectors for gene transfer and expression. BioTechniques 1989; 7: 980-984.
47. Alton K et al. Production, characterization and biological effects of recombinant DNA derived human IFN-α and IFN-γ analogs. In: De Maeyer E, Schellenkens H (eds). The Biology of the Interferon System. Elsevier: Amsterdam, 1983, pp 119-128.
48. Markowitz D, Goff S, Bank A. A safe packaging line for gene transfer: separating viral genes on two different plasmids. J Virol 1988; 62: 1120-1124.
49. Markowitz D, Goff S, Bank A. Construction and use of a safe and efficient amphotropic packaging cell line. Virology 1988; 167: 400-406.
50. Malorni W, Rivabene R, Santini MT, Donelli G. N-acetylcysteine inhibits apoptosis and decreases viral particles in HIV-chronically infected U937 cells. FEBS Lett 1993; 327: 75-78.